Utidelone and capecitabine for HER2-negative breast cancer with brain metastases
Treatments studied
Part of Brain & nervous system, Cancer, Skin clinical trials.
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have HER2-negative breast cancer that has spread to other parts of the body and to the brain.
- You must have at least one brain tumor that can be measured on an MRI scan.
- You must be 18 years or older and able to care for yourself (ECOG score 0 or 1).
- You must have had no more than 3 prior chemotherapy treatments for advanced breast cancer.
- You must not have certain other medical conditions like uncontrolled seizures, bleeding problems, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs (Utidelone and Capecitabine) for people with triple-negative breast cancer that has spread to the brain. The goal is to see if the combination can shrink or control the brain tumors.
This trial tests a combination of two chemotherapy drugs, utidelone and capecitabine, for women with HER2-negative breast cancer that has spread to other parts of the body. The goal is to see if this combination can help shrink tumors and slow the cancer's growth.
This trial tests whether adding a study drug called UTD1 to capecitabine can shrink or control breast cancer that has spread to the brain. It’s for people with HER2-negative metastatic breast cancer who have brain metastases and meet specific safety and lab requirements.
This trial tests a combination of two drugs, utidelone and bevacizumab, for people with a type of lung cancer (non-squamous non-small cell) that has spread to the brain. The goal is to see if this treatment can shrink tumors in the brain and elsewhere.
This Phase 3 study compares two chemotherapy combinations to treat HER2-negative breast cancer that has spread or is locally advanced. It aims to find which plan works better and has an acceptable side-effect profile for people who have had prior taxane treatment (in earlier-stage settings).
This trial compares utidelone with docetaxel in people with HER2-negative advanced or metastatic breast cancer. It aims to see which treatment works better and is safer for controlling the cancer and helping patients live longer.
Hear when a new HER2-negative Breast Cancer Patients With Brain Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.